Project Grant R01AG107075
Award Date 9/1/26
Completion Date 5/31/30
Dollars Obligated $132K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Philadelphia, PA 19140, USA
Similar Awards
- The National Institute on Aging awarded Georgetown University $156,000 on September 1, 2026, under the Aging Research program (CFDA 93.866) to investigate mitigation strategies for network dysfunction in Alzheimer's disease pathology. The project tests whether mild hyperpolarization can stabilize hippocampal network activity despite amyloid-beta-related impairment of excitatory amino acid transporters. The research quantifies sharp wave-ripples in ex vivo hippocampal slices from 5XFAD transgenic...
- The National Institute on Aging, part of the Department of Health and Human Services, awarded $170,668 to the University of California, San Diego on October 24, 2025, under the Aging Research program (CFDA 93.866) to support research into s-nitrosylated phospholipase D3 in Alzheimer's disease pathophysiology. The funded research investigates the mechanistic role of s-nitrosylated phospholipase D3 (SNO-PLD3) in Alzheimer's disease. The work builds on prior mass spectrometry findings that...
- The National Institute on Aging awarded Boston University Medical Campus $110,228 in project grant funding on February 7, 2027, to develop and validate a novel cellular model of entorhinal cortex layer II vulnerability in Alzheimer's disease under the Aging Research program (CFDA 93.866). The project will develop in vitro models using induced pluripotent stem cells (iPSCs) and direct fibroblast conversion to generate entorhinal cortex layer II (ECII)-like neurons for studying Alzheimer's disease...
- The National Institute on Aging awarded Icahn School of Medicine at Mount Sinai $230,388 on March 4, 2026, under the Aging Research program (CFDA 93.866) to dissect the role of the PICALM/EED locus on myeloid cells in Alzheimer's disease. The recipient will conduct research to understand how an Alzheimer's disease risk enhancer on chromosome 11 influences expression of two target genes—PICALM (phosphatidylinositol binding clathrin assembly protein) and EED (embryonic ectoderm development)—and to...
- The National Institute on Aging, a component of the Department of Health and Human Services, awarded Massachusetts Institute of Technology $596,050 on September 15, 2026, under the Aging Research program (CFDA 93.866) to investigate fuzzy coat dynamics of post-translationally modified tau aggregation. The project examines structural properties of tau, a microtubule-associated protein whose aggregation hallmarks Alzheimer's disease and twenty other neurodegenerative diseases. The research tests...
- The National Institute on Aging awarded Drexel University $420,554 under Aging Research (CFDA 93.866) on September 1, 2026, to establish an integrated system for studying senescence and aging in the central nervous system. The award funds two research aims: characterization of the molecular and functional consequences of senescence in astrocyte and neuronal cultures, and evaluation of senescence impact in a multicellular context using hiPSC-derived vascularized cortical organoids. Single-cell...
- The National Institute on Aging awarded the University of Virginia $583,815 on August 15, 2026, under the Aging Research program (CFDA 93.866) to support research into oligodendrocyte lineage dysfunction during aging and Alzheimer's disease. The project aims to understand how myelin loss—a pathology common to both aging and Alzheimer's disease—develops in the central nervous system and to identify therapeutic targets for cognitive impairment. The research focuses on oligodendrocyte precursor...
- The National Institute on Aging awarded New York University $642,063 under the Aging Research program (CFDA 93.866) on January 15, 2026, to investigate gabaergic circuit targets for modulating entorhinal cortex and hippocampal dynamics in Alzheimer's disease. The research examines vasoactive intestinal peptide and cholecystokinin inhibitory neuron microcircuits within hippocampal area CA1, with the hypothesis that modulating activity in these circuits can improve lateral entorhinal cortex–CA1...
- The National Institute on Aging awarded Emory University $643,613 on April 1, 2026, under the Aging Research program (CFDA 93.866) to discover glycosylation-based disease processes and identify glyco-biomarkers and targets for improving Alzheimer's disease diagnosis, prognosis, and intervention. The recipient will perform innovative research using an integrated platform of intact glycopeptide-based quantitative glycoproteomics and systems biology to elucidate brain glycoproteome alterations in...
- The National Institute on Aging awarded the University of Southern California $149,190 on August 6, 2026, under the Aging Research program (CFDA 93.866) to investigate how early-stage Alzheimer's disease disrupts coordinated release dynamics between acetylcholine and norepinephrine in the cortex and how this discoordination impairs cognitive performance. The research characterizes the evolution of coordinated cortical acetylcholine and norepinephrine release activity in vivo in wildtype mice,...